Girard Partners Ltd. Abb Vie Inc. Transaction History

Girard Partners Ltd.

  • $1.06 Billion
  • Q2 2024

A detailed history of Girard Partners Ltd. transactions in Abb Vie Inc. stock. As of the latest transaction made, Girard Partners Ltd. holds 8,710 shares of ABBV stock, worth $1.59 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
8,710
Previous 8,948 2.66%
Holding current value
$1.59 Million
Previous $1.63 Million 8.35%
% of portfolio
0.14%
Previous 0.15%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024
SELL
$154.79 - $180.76 $36,840 - $43,020
-238 Reduced 2.66%
8,710 $1.49 Million
Q1 2024

May 13, 2024
SELL
$159.82 - $182.1 $64,567 - $73,568
-404 Reduced 4.32%
8,948 $1.63 Million
Q4 2023

Feb 09, 2024
BUY
$137.6 - $154.97 $4,540 - $5,114
33 Added 0.35%
9,352 $1.45 Million
Q3 2023

Nov 02, 2023
SELL
$133.59 - $154.65 $51,164 - $59,230
-383 Reduced 3.95%
9,319 $1.39 Million
Q2 2023

Aug 15, 2023
SELL
$132.51 - $164.9 $240,903 - $299,788
-1,818 Reduced 15.78%
9,702 $1.31 Million
Q1 2023

May 12, 2023
SELL
$144.61 - $166.54 $133,330 - $153,549
-922 Reduced 7.41%
11,520 $1.84 Million
Q4 2022

Jan 26, 2023
BUY
$138.31 - $165.87 $7,330 - $8,791
53 Added 0.43%
12,442 $0
Q3 2022

Oct 20, 2022
SELL
$134.21 - $153.93 $1,207 - $1,385
-9 Reduced 0.07%
12,389 $1.66 Million
Q2 2022

Jul 26, 2022
SELL
$137.62 - $174.96 $206,567 - $262,614
-1,501 Reduced 10.8%
12,398 $1.9 Million
Q1 2022

Apr 27, 2022
SELL
$131.98 - $163.75 $872,123 - $1.08 Million
-6,608 Reduced 32.22%
13,899 $2.25 Million
Q4 2021

Feb 02, 2022
BUY
$107.43 - $135.93 $384,169 - $486,085
3,576 Added 21.12%
20,507 $2.78 Million
Q3 2021

Nov 01, 2021
BUY
$106.4 - $120.78 $1.61 Million - $1.82 Million
15,105 Added 827.22%
16,931 $1.83 Million
Q3 2021

Nov 01, 2021
SELL
$106.4 - $120.78 $979,837 - $1.11 Million
-9,209 Reduced 83.45%
1,826 $1.83 Million
Q2 2021

Aug 10, 2021
BUY
$105.21 - $117.21 $136,562 - $152,138
1,298 Added 13.33%
11,035 $1.24 Million
Q1 2021

May 06, 2021
BUY
$102.3 - $112.62 $97,185 - $106,989
950 Added 10.81%
9,737 $1.05 Million
Q4 2020

Feb 02, 2021
SELL
$80.49 - $108.67 $63,909 - $86,283
-794 Reduced 8.29%
8,787 $941,000
Q3 2020

Nov 13, 2020
SELL
$85.91 - $100.83 $77,920 - $91,452
-907 Reduced 8.65%
9,581 $839,000
Q2 2020

Aug 10, 2020
SELL
$73.37 - $98.18 $26,339 - $35,246
-359 Reduced 3.31%
10,488 $1.03 Million
Q1 2020

May 01, 2020
SELL
$64.5 - $97.79 $25,413 - $38,529
-394 Reduced 3.51%
10,847 $826,000
Q4 2019

Feb 03, 2020
BUY
$72.13 - $90.25 $17,527 - $21,930
243 Added 2.21%
11,241 $995,000
Q3 2019

Nov 01, 2019
SELL
$62.98 - $75.72 $69,718 - $83,822
-1,107 Reduced 9.14%
10,998 $832,000
Q2 2019

Aug 12, 2019
SELL
$65.7 - $83.98 $2,430 - $3,107
-37 Reduced 0.3%
12,105 $880,000
Q1 2019

May 08, 2019
SELL
$77.14 - $90.79 $58,934 - $69,363
-764 Reduced 5.92%
12,142 $978,000
Q4 2018

Feb 11, 2019
SELL
$77.85 - $96.01 $56,441 - $69,607
-725 Reduced 5.32%
12,906 $1.19 Million
Q3 2018

Nov 09, 2018
SELL
$88.91 - $98.84 $55,746 - $61,972
-627 Reduced 4.4%
13,631 $1.29 Million
Q2 2018

Aug 07, 2018
BUY
$89.78 - $106.23 $1.28 Million - $1.51 Million
14,258 New
14,258 $1.32 Million
Q1 2018

Apr 18, 2018
SELL
$92.01 - $123.21 $1.29 Million - $1.72 Million
-13,990 Closed
0 $0
Q4 2017

Feb 07, 2018
BUY
$89.56 - $98.21 $75,409 - $82,692
842 Added 6.4%
13,990 $1.35 Million
Q3 2017

Nov 08, 2017
SELL
$69.85 - $89.22 $36,112 - $46,126
-517 Reduced 3.78%
13,148 $1.17 Million
Q2 2017

Aug 08, 2017
BUY
N/A
13,665
13,665 $991,000

Others Institutions Holding ABBV

# of Institutions
3,849
Shares Held
1.25B
Call Options Held
16.8M
Put Options Held
12.2M
View Full List

About AbbVie Inc.

ABBV Quotes by TradingView
  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $323B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Girard Partners Ltd. Portfolio

Follow Girard Partners Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Girard Partners Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Girard Partners Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email